Navigation Links
Particle Sciences, Inc. and Dow Corning Corporation Cooperate to Develop New Product Technology
Date:10/6/2009

BETHLEHEM, Pa., Oct. 6 /PRNewswire/ -- Particle Sciences has announced today that they have been engaged by Dow Corning to develop technology for a key Dow Corning product development project. Bruce Frank, Director of Project Management for Particle Sciences remarked, "This is a little outside our normal focus of pharmaceutical development but the technological approach is perfectly analogous. We expect to provide a novel and robust solution that allows Dow Corning to develop a product that will benefit its customers." Andrew Loxley, Director, New Technologies for Particle Sciences added that "Particle Sciences is leveraging its extensive experience and expertise to evaluate a number of technologies deemed suitable for the complex performance characteristics of this particular product. Developing a suitable approach will lead directly to a fast-track scale-up and technology transfer program to commercialize this product." Additional terms of the agreement have not been released.

About Dow Corning

Dow Corning Corporation provides performance-enhancing solutions to serve the diverse needs of more than 25,000 customers worldwide. A global leader in silicones, silicon-based technology and innovation, Dow Corning offers more than 7,000 products and services via the company's Dow Corning(®) and XIAMETER(®) brands. Dow Corning is a joint venture equally owned by The Dow Chemical Company and Corning, Incorporated. More than half of Dow Corning's annual sales are outside the United States.

About Particle Sciences

Particle Sciences is a Bethlehem, PA based Contract Formulation and Analytical Services company that focuses on the Pharmaceutical Industry. Their services include the development of novel encapsulation and drug delivery technologies including drug-device combination products, nanoparticle production and characterization, cGMP analytical services and clinical drug product manufacturing for Phase I and II clinical trials. Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861-4701 for information.

    Maureen Cochran 610-861-4701

SOURCE Particle Sciences


'/>"/>
SOURCE Particle Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. New CapSure™ Cleanroom Wiper from Berkshire Corporation Captures and Retains 42 Times More Contaminant Particles
2. Engineers produce how-to guide for controlling the structure of nanoparticles
3. New discovery reveals fate of nanoparticles in human cells
4. NOVAVAX Announces Positive Results for the Second Phase II Clinical Trial of its Trivalent Seasonal Influenza Virus-like Particle (VLP) Vaccine Candidate
5. Bio-enabled, surface-mediated approach produces nanoparticle composites
6. NOVAVAX Virus-Like Particle Vaccine Protects Against 2009 Pandemic H1N1 Influenza Virus
7. Capping a two-faced particle gives duke engineers complete control
8. Nanotech particles affect brain development in mice
9. Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commercialization
10. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
11. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... SHANGHAI , Jan. 19, 2017 /PRNewswire -- ... medical device open-access capability and technology platform, today ... a leading biology focused preclinical drug discovery contract ... Biosciences will become a wholly-owned subsidiary of WuXi, ... core competences and providing greater services. The acquisition ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., today ... , Ph.D., as chief executive officer, as well ... Dr. Schmidt brings to ArmaGen more than 17 years ... and development of biotherapeutics and pharmaceuticals. ... the diverse experience and skillset necessary to lead ...
(Date:1/19/2017)... Minneapolis, Minnesota (PRWEB) , ... January 19, 2017 ... ... contract research organization with services spanning the full spectrum of drug and device ... clinical research services to pharma/device companies and clinicians, today announced Verified Clinical ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... essential device-to-computer interconnect using USB or PCI Express, announced the ZEM5310 USB 3.0 ... E FPGA into a compact business-card sized form factor suitable for prototyping, testing, ...
Breaking Biology Technology:
(Date:1/6/2017)... 2017  Delta ID Inc., a leader in consumer-grade ... automotive at CES® 2017. Delta ID has collaborated with ... the use of iris scanning as a secure, reliable ... in a car, and as a way to elevate ... Delta ID and Gentex will demonstrate (booth #7326 ...
(Date:12/22/2016)... Dec. 20, 2016  As part of its longstanding mission ... personal genetics company, recently released its latest children,s book, titled ... book focuses on the topics of inheritance and variation of ... (NGSS) taught in elementary school classrooms in the US. ... by illustrator Ariana Killoran , whose previous book with ...
(Date:12/19/2016)... España y TORONTO , 19 de diciembre de ... Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un anticuerpo ... varios tipos de tumor en 2017, con múltiples sitios previstos a ... ... con objetivo en el factor inhibidor de leucemia (LIF), una citoquina ...
Breaking Biology News(10 mins):